Stine Seed led a $25m Series B round in Vyriad.

Stine Seed, a venture capital firm, led a $25m Series B round in Vyriad, a clinical-stage biotechnology company developing targeted genetic therapies for cancer and other serious diseases. “Our mission is to transform the future of medicine with targeted genetic therapies. We are excited to launch the first-in-human Phase 1 clinical trial of VV169 and bring this therapy to patients. Our work builds on years of research and optimization around cell-specific targeting, G-protein engineering, and immune evasion — the core capabilities needed to enable effective CAR T therapies. We’re looking forward to validating our delivery technology platform and our in vivo CAR T therapeutic candidates in the clinic,” Dr. Stephen Russell, Vyriad Co-Founder and CEO.